Pathological Jaundice: Diagnosis and Management

Definition and Clinical Threshold

The American College of Radiology states that pathological jaundice is hyperbilirubinemia that results from underlying disease processes causing bilirubin overproduction, impaired conjugation, biliary obstruction, or hepatic inflammation, requiring immediate investigation and treatment to prevent permanent organ damage, particularly neurological complications in neonates 1

Neonatal cholestasis (conjugated hyperbilirubinemia lasting >2-3 weeks) has genetic/metabolic causes in 25-30% of cases, with incidence of 1 in 2,500 live births 3
The American Academy of Pediatrics recommends that infants with risk factors (gestational age <38 weeks, exclusive breastfeeding with poor intake, East Asian ethnicity) require aggressive monitoring protocols 2
Viral hepatitis A in neonates: >90% of infections in children <6 years are asymptomatic, but stool shedding can occur for up to 10 weeks, with infectivity highest 14-21 days before to 8 days after jaundice onset 4

The American College of Radiology identifies four main pathophysiological categories of jaundice in adults: bilirubin overproduction, impaired conjugation, biliary obstruction, and hepatic inflammation 1, 5
Biliary obstruction (conjugated hyperbilirubinemia) is caused by common bile duct stones (14%) and malignancy (6.2% in U.S. studies) 1, 5
Hepatic inflammation is caused by hepatitis, alcoholic liver disease (16%), sepsis (22%), and cirrhosis decompensation (20.5%) 5

The American College of Radiology recommends that initial workup must include hepatic profile with fractionated bilirubin (conjugated vs. unconjugated), alkaline phosphatase, ALT, AST, total protein, and complete blood count 1
Abdominal ultrasound is the first-line imaging modality, followed by MRCP for biliary tree evaluation when obstruction is suspected 1

The American College of Radiology states that treatment is directed at the underlying etiology identified through laboratory and imaging evaluation 1
Obstructive causes are treated with ERCP with stone extraction or stenting for malignant obstruction 1
Hepatocellular causes are treated by addressing underlying hepatitis, discontinuing offending drugs, managing alcoholic liver disease or sepsis 5